Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 8 of 198 for:    Venetoclax

Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03319901
Recruitment Status : Recruiting
First Posted : October 24, 2017
Last Update Posted : November 28, 2018
Sponsor:
Collaborator:
AbbVie
Information provided by (Responsible Party):
Daniel J. DeAngelo, MD, PhD, Dana-Farber Cancer Institute

Brief Summary:

This research study is studying a medication called Venetoclax and a chemotherapy regimen as a possible treatment for Acute Lymphoblastic Leukemia.

The drugs involved in this study are:

  • Venetoclax
  • Standard Chemotherapy (which includes cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, 6-mercaptopurine, etoposide, and cytarabine

Condition or disease Intervention/treatment Phase
Leukemia Drug: Venetoclax Drug: Standard Chemotherapy Phase 1

Detailed Description:

This research study is a Phase I clinical trial, which tests the safety of an investigational drug and drug combination and also tries to define the appropriate dose of the investigational drug and drug combination to use for further studies. "Investigational" means that the drug and drug combination is being studied.

The FDA (the U.S. Food and Drug Administration) has not approved Venetoclax for this specific disease, but it has been approved for other uses.

Venetoclax is an inhibitor of Bcl-2. Bcl-2 is critical for keeping cancer cells alive.

By inhibiting Bcl-2, venetoclax promotes cancer cell death. This drug is currently being used in other clinical trials for people with certain types of leukemia, lymphoma, and multiple myeloma. There is some evidence from those and other laboratory trials that venetoclax may kill cancer cells and cause tumors to shrink.

In this research study, the investigators are investigating how safe the combination of Venetoclax and standard chemotherapy is and how it affects this disease.. The participant will be given Venetoclax alone first and the standard chemotherapies will be given in combination. This study aims to provide information to help determine the dose of Venetoclax , in combination with standard chemotherapy, affects this disease the best and which dose is the safest.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 22 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase Ib Study of the Combination of Venetoclax With Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
Actual Study Start Date : October 30, 2017
Estimated Primary Completion Date : April 30, 2020
Estimated Study Completion Date : April 30, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Leukemia
Drug Information available for: Venetoclax

Arm Intervention/treatment
Experimental: Venetoclax + Chemotherapy
  • Venetoclax is administered orally once daily for 21 days in each cycle
  • Standard Chemotherapy will be administered every 28 days
Drug: Venetoclax

Venetoclax is an inhibitor of Bcl-2. Bcl-2 is critical for keeping cancer cells alive.

By inhibiting Bcl-2, venetoclax promotes cancer cell death.

Other Name: ABT199

Drug: Standard Chemotherapy
Standard treatment of chemotherapy is administered




Primary Outcome Measures :
  1. Maximum Tolerated Dose [ Time Frame: 2 years ]
    To determine the maximum tolerated dose (MTD) of venetoclax in combination with chemotherapy in patients with newly diagnosed Acute Lymphoblastic Leukemia (ALL)


Secondary Outcome Measures :
  1. To Evaluate The Safety of the Combination [ Time Frame: 2 years ]

    To evaluate the safety of this combination in a dose expansion cohort.

    The proportion of patients having a grade 3 or higher adverse event will be estimated with a 95% confidence interval in the expansion cohort.


  2. Complete Response [ Time Frame: 2 years ]
    To determine the efficacy: complete response (CR) with incomplete marrow recovery (CRi) of venetoclax in combination with chemotherapy in patients with newly diagnosed ALL

  3. Progression Free Survival [ Time Frame: 2 years ]
    To determine the duration of response: progressive-free survival (PFS) and overall survival (OS) of venetoclax in combination with chemotherapy in patients with newly diagnosed ALL

  4. Overall Survival [ Time Frame: 2 years ]
    To determine the duration of response: progressive-free survival (PFS) and overall survival (OS) of venetoclax in combination with chemotherapy in patients with newly diagnosed ALL

  5. Minimal Residual Disease [ Time Frame: 2 years ]
    To determine the rate of minimal residual disease (MRD) negativity in patients achieving CR/CRi and its correlation with disease-free survival (DFS) and OS

  6. Disease Free Survival [ Time Frame: 2 years ]
    To determine the rate of minimal residual disease (MRD) negativity in patients achieving CR/CRi and its correlation with disease-free survival (DFS) and OS

  7. Change in expression of BCL-2 family proteins: BCL-2 [ Time Frame: 2 years ]

    To measure expression and function of Bcl-2 family proteins and its modulation by venetoclax in ALL blasts.

    The change in expression of BCL-2 family proteins from baseline to the time of each response assessment will be measured including BCL-2 and summary statistics including the median and interquartile range of the change will be reported for all patients in the expansion cohort and also summarized for those achieving a CR/CRi and those patients who do not achieve a CR/CRi.

    This is based on section 9.1: We plan to collect bone marrow and peripheral blood samples at baseline, at the time of clinical response assessment and at the time of progression for correlative studies. These will be done in the laboratory of Dr. Marina Konopleva at MDACC and Dr. Tony Letai at DFCI.


  8. Change in expression of BCL-2 family proteins: BCL-XL [ Time Frame: 2 years ]

    To measure expression and function of Bcl-2 family proteins and its modulation by venetoclax in ALL blasts.

    The change in expression of BCL-2 family proteins from baseline to the time of each response assessment will be measured including BCL-XL and summary statistics including the median and interquartile range of the change will be reported for all patients in the expansion cohort and also summarized for those achieving a CR/CRi and those patients who do not achieve a CR/CRi.

    This is based on section 9.1: We plan to collect bone marrow and peripheral blood samples at baseline, at the time of clinical response assessment and at the time of progression for correlative studies. These will be done in the laboratory of Dr. Marina Konopleva at MDACC and Dr. Tony Letai at DFCI.


  9. Change in expression of BCL-2 family proteins: MCL-1 (anti-apoptotic) [ Time Frame: 2 years ]

    To measure expression and function of Bcl-2 family proteins and its modulation by venetoclax in ALL blasts.

    The change in expression of BCL-2 family proteins from baseline to the time of each response assessment will be measured including MCL-1 (anti-apoptotic) and summary statistics including the median and interquartile range of the change will be reported for all patients in the expansion cohort and also summarized for those achieving a CR/CRi and those patients who do not achieve a CR/CRi.

    This is based on section 9.1: We plan to collect bone marrow and peripheral blood samples at baseline, at the time of clinical response assessment and at the time of progression for correlative studies. These will be done in the laboratory of Dr. Marina Konopleva at MDACC and Dr. Tony Letai at DFCI.


  10. Change in expression of BCL-2 family proteins: BCL-2 homology 3 (BH3) [ Time Frame: 2 years ]

    To measure expression and function of Bcl-2 family proteins and its modulation by venetoclax in ALL blasts.

    The change in expression of BCL-2 family proteins from baseline to the time of each response assessment will be measured including BCL-2 homology 3 (BH3) and summary statistics including the median and interquartile range of the change will be reported for all patients in the expansion cohort and also summarized for those achieving a CR/CRi and those patients who do not achieve a CR/CRi.

    This is based on section 9.1: We plan to collect bone marrow and peripheral blood samples at baseline, at the time of clinical response assessment and at the time of progression for correlative studies. These will be done in the laboratory of Dr. Marina Konopleva at MDACC and Dr. Tony Letai at DFCI.


  11. Change in expression of BCL-2 family proteins: BIM [ Time Frame: 2 years ]

    To measure expression and function of Bcl-2 family proteins and its modulation by venetoclax in ALL blasts.

    The change in expression of BCL-2 family proteins from baseline to the time of each response assessment will be measured including BIM and summary statistics including the median and interquartile range of the change will be reported for all patients in the expansion cohort and also summarized for those achieving a CR/CRi and those patients who do not achieve a CR/CRi.

    This is based on section 9.1: We plan to collect bone marrow and peripheral blood samples at baseline, at the time of clinical response assessment and at the time of progression for correlative studies. These will be done in the laboratory of Dr. Marina Konopleva at MDACC and Dr. Tony Letai at DFCI.


  12. Change in expression of BCL-2 family proteins: BID [ Time Frame: 2 years ]

    To measure expression and function of Bcl-2 family proteins and its modulation by venetoclax in ALL blasts.

    The change in expression of BCL-2 family proteins from baseline to the time of each response assessment will be measured including BID and summary statistics including the median and interquartile range of the change will be reported for all patients in the expansion cohort and also summarized for those achieving a CR/CRi and those patients who do not achieve a CR/CRi.

    This is based on section 9.1: We plan to collect bone marrow and peripheral blood samples at baseline, at the time of clinical response assessment and at the time of progression for correlative studies. These will be done in the laboratory of Dr. Marina Konopleva at MDACC and Dr. Tony Letai at DFCI.


  13. Change in expression of BCL-2 family proteins: BAD [ Time Frame: 2 years ]

    To measure expression and function of Bcl-2 family proteins and its modulation by venetoclax in ALL blasts.

    The change in expression of BCL-2 family proteins from baseline to the time of each response assessment will be measured including BAD and summary statistics including the median and interquartile range of the change will be reported for all patients in the expansion cohort and also summarized for those achieving a CR/CRi and those patients who do not achieve a CR/CRi.

    This is based on section 9.1: We plan to collect bone marrow and peripheral blood samples at baseline, at the time of clinical response assessment and at the time of progression for correlative studies. These will be done in the laboratory of Dr. Marina Konopleva at MDACC and Dr. Tony Letai at DFCI.


  14. Change in expression of BCL-2 family proteins: NOXA [ Time Frame: 2 years ]

    To measure expression and function of Bcl-2 family proteins and its modulation by venetoclax in ALL blasts.

    The change in expression of BCL-2 family proteins from baseline to the time of each response assessment will be measured including NOXA and summary statistics including the median and interquartile range of the change will be reported for all patients in the expansion cohort and also summarized for those achieving a CR/CRi and those patients who do not achieve a CR/CRi.

    This is based on section 9.1: We plan to collect bone marrow and peripheral blood samples at baseline, at the time of clinical response assessment and at the time of progression for correlative studies. These will be done in the laboratory of Dr. Marina Konopleva at MDACC and Dr. Tony Letai at DFCI.


  15. Change in expression of BCL-2 family proteins: PUMA [ Time Frame: 2 years ]

    To measure expression and function of Bcl-2 family proteins and its modulation by venetoclax in ALL blasts.

    The change in expression of BCL-2 family proteins from baseline to the time of each response assessment will be measured including PUMA and summary statistics including the median and interquartile range of the change will be reported for all patients in the expansion cohort and also summarized for those achieving a CR/CRi and those patients who do not achieve a CR/CRi.

    This is based on section 9.1: We plan to collect bone marrow and peripheral blood samples at baseline, at the time of clinical response assessment and at the time of progression for correlative studies. These will be done in the laboratory of Dr. Marina Konopleva at MDACC and Dr. Tony Letai at DFCI.


  16. Change in expression of BCL-2 family proteins: HRK (pro-apoptotic) [ Time Frame: 2 years ]

    To measure expression and function of Bcl-2 family proteins and its modulation by venetoclax in ALL blasts.

    The change in expression of BCL-2 family proteins from baseline to the time of each response assessment will be measured including HRK (pro-apoptotic) and summary statistics including the median and interquartile range of the change will be reported for all patients in the expansion cohort and also summarized for those achieving a CR/CRi and those patients who do not achieve a CR/CRi.

    This is based on section 9.1: We plan to collect bone marrow and peripheral blood samples at baseline, at the time of clinical response assessment and at the time of progression for correlative studies. These will be done in the laboratory of Dr. Marina Konopleva at MDACC and Dr. Tony Letai at DFCI.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with previously untreated acute lymphoblastic leukemia (B-cell or T-cell)
  • Bone marrow involvement with ≥20% lymphoblasts
  • Age ≥ 60 Years

OR

  • Patients with relapsed or refractory acute lumphoblastic leukemia (B-cell or T-cell) defined as receiving one or more cytotoxic containing regimens
  • Bone marrow involvement with ≥5% lymphoblasts
  • Age ≥ 18 Years
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤2 (Refer to Appendix D)
  • Adequate organ function

    • Serum total bilirubin ≤1.5 x upper limit of normal (ULN) or ≤3 x ULN for patients with Gilbert's disease
    • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3.0 x ULN, unless clearly due to disease involvement
    • Creatinine clearance >50 mL/min (calculated according to institutional standards or using Cockcroft-Gault or Modification of Diet in Renal Disease (MDRD) formula)
  • Women of childbearing potential must have a negative serum or urine beta human chorionic gonadotropin (β-hCG) pregnancy test result within 14 days prior to the first dose of study drugs and must agree to use an effective contraception method during the study and for 30 days following the last dose of study drug. Women of non- childbearing potential are those who are postmenopausal greater than 1 year or who have had a bilateral tubal ligation or hysterectomy. Men who have partners of childbearing potential must agree to use an effective contraceptive method during the study and for 30 days following the last dose of study drug
  • Patients or their legally authorized representative must provide written informed consent

Exclusion Criteria:

  • Ph-positive ALL, Burkitt's leukemia/lymphoma, or lymphoblastic lymphoma
  • Patient is pregnant or breastfeeding
  • Patients with uncontrolled infection
  • Hepatitis B or C infection, or known seropositivity for human immunodeficiency virus (HIV)
  • Major surgery or radiation therapy within 4 weeks prior to the first study dose
  • Systemic chemotherapy/radiotherapy/investigational therapy within 14 days (with the exception of hydroxyurea and/or dexamethasone, or one dose of cytarabine) prior to starting therapy
  • Symptomatic or untreated leptomeningeal disease or spinal cord compression
  • Patients with active heart disease (New York Heart Association (NYHA) class 3-4 as assessed by history and physical examination, unstable angina/stroke/myocardial infarction within the last 6 months)
  • Patients with a cardiac ejection fraction (as measured by either Multi Gated Acquisition (MUGA) or echocardiogram (EKG)) <40%
  • History of another primary invasive malignancy that has not been definitively treated or in remission for at least 2 years. Patients with non-melanoma skin cancers or with carcinomas in situ are eligible regardless of the time from diagnosis (including concomitant diagnoses)
  • Concurrent use of warfarin
  • Received Cytochrome P450 3A (CYP3A) inhibitors (such as fluconazole, ketoconazole, voriconazole, and clarithromycin) within 3 days of starting venetoclax; received strong CYP3A inducers (such as rifampin, rifabutin, phenytoin, carbamazepine, and St. John's Wort) within 3 days of starting venetoclax
  • Consumed grapefruit, grapefruit products, Seville oranges, or star fruit within 3 days prior to starting venetoclax
  • Prior treatment with venetoclax
  • Malabsorption syndrome or other conditions that preclude enteral route of administration
  • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that in the opinion of the investigator may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and/or would make the patient inappropriate for enrollment into this study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03319901


Contacts
Layout table for location contacts
Contact: Daniel DeAngelo, MD, PhD 617-632-2645 Daniel_DeAngelo@DFCI.Harvard.Edu

Locations
Layout table for location information
United States, Massachusetts
Dana Farber Cancer Institute Recruiting
Boston, Massachusetts, United States, 02115
Contact: Daniel DeAngelo, MD, PhD    617-632-2645    Daniel_DeAngelo@DFCI.Harvard.Edu   
Principal Investigator: Daniel DeAngelo, MD, PhD         
United States, Texas
MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Nitin Jain, MD    713-745-6080    njain@mdanderson.org   
Principal Investigator: Nitin Jain, MD         
Sponsors and Collaborators
Dana-Farber Cancer Institute
AbbVie
Investigators
Layout table for investigator information
Principal Investigator: Daniel DeAngelo, MD, PhD Dana-Farber Cancer Institute

Layout table for additonal information
Responsible Party: Daniel J. DeAngelo, MD, PhD, Principal Investigator, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier: NCT03319901     History of Changes
Other Study ID Numbers: 16-648
First Posted: October 24, 2017    Key Record Dates
Last Update Posted: November 28, 2018
Last Verified: November 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Daniel J. DeAngelo, MD, PhD, Dana-Farber Cancer Institute:
Leukemia
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia
Neoplasms by Histologic Type
Neoplasms
Venetoclax
Antineoplastic Agents